The advent of CAR T-cell therapy and bispecific antibodies has revolutionized care for patients with B-cell non-Hodgkin’s lymphomas, but they also come with inflammatory and neurological safety concerns that may be unfamiliar to emergency department clinicians. In this activity, clinicians will learn directly from Drs. Joshua Brody and Jeremy Abramson how to recognize, evaluate, and treat these adverse reactions according to guidelines.
Upon completion of this activity, participants should be better able to:
Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor, Medicine
Harvard Medical School
Boston, MA
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
